Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 7/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.54 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.54 |
| ▸ | ST6GAL1 | P15907 | 3/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20769283 | 1.00 | P2RY2 (0.57) | P2RY2TSHRGLAP2RY6LMNA | |
| SCHEMBL2948365 | 1.00 | P2RY2 (0.57) | P2RY2TSHRGLAP2RY6LMNA | |
| SCHEMBL25389430 | 0.92 | P2RY2 (0.55) | P2RY2TSHRGLAP2RY6LMNA | |
| SCHEMBL18007475 | 0.91 | P2RY2 (0.54) | P2RY2TSHRGLAP2RY6LMNA | |
| SCHEMBL16412082 | 0.91 | P2RY2 (0.54) | P2RY2TSHRGLAP2RY6LMNA | |
| SCHEMBL20769285 | 0.91 | P2RY2 (0.58) | P2RY2TSHRGLAP2RY6LMNA | |
| SCHEMBL1526683 | 0.91 | P2RY2 (0.67) | P2RY2P2RY6P2RY4 | |
| SCHEMBL3501914 | 0.91 | P2RY2 (0.67) | P2RY2P2RY6P2RY4 | |
| SCHEMBL20769296 | 0.90 | P2RY2 (0.57) | P2RY2TSHRGLAP2RY6LMNA | |
| SCHEMBL843976 | 0.90 | P2RY2 (0.57) | P2RY2TSHRGLAP2RY6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 357 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114703184-B | LPA inhibitors and uses thereof | 厦门甘宝利生物医药有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-117264948-B | RNAi inhibitor for inhibiting expression of angiotensinogen gene and application thereof | 广州必贝特医药股份有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-117597443-A | RNA inhibitor for inhibiting hepatitis B virus gene expression and application thereof | 厦门甘宝利生物医药有限公司 | 2024-02-23 | — | — | CN | claimed |
| US-11884919-B2 | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-30 | — | — | US | claimed |
| CN-115851723-B | RNA inhibitor for inhibiting LPA gene expression and application thereof | 厦门甘宝利生物医药有限公司 | 2023-10-03 | — | — | CN | claimed |
| CN-116814621-A | RNA inhibitor for inhibiting APOC3 gene expression and application thereof | 厦门甘宝利生物医药有限公司 | 2023-09-29 | — | — | CN | claimed |
| US-20230304058-A1 | NOVEL 5'CAP ANALOG HAVING CAP2 STRUCTURE AND PREPARATION METHOD THEREFOR | SHENZHEN RHEGEN BIOTECHNOLOGY CO., LTD. (CN) | 2023-09-28 | — | — | US | claimed |
| EP-4202053-A1 | NOVEL 5'CAP ANALOG HAVING CAP2 STRUCTURE AND PREPARATION METHOD THEREFOR | Shenzhen Rhegen Biotechnology Co., Ltd. (CN) | 2023-06-28 | — | — | EP | claimed |
| CN-115851723-A | RNA inhibitor for inhibiting expression of LPA gene and application thereof | 厦门甘宝利生物医药有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-114940991-B | RNA inhibitor for inhibiting hepatitis B virus gene expression and application thereof | 厦门甘宝利生物医药有限公司 | 2023-02-03 | — | — | CN | claimed |
| US-9868950-B2 | Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | claimed |
| EP-3109321-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | Alnylam Pharmaceuticals, Inc. (US) | 2016-12-28 | — | — | EP | claimed |
| US-20160194633-A1 | Lipid Formulated Compositions and Methods for Inhibiting Expression of Serum Amyloid A Gene | BANK OF AMERICA, N.A. | 2016-07-07 | — | — | US | claimed |
| EP-2334793-B1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | ALNYLAM PHARMACEUTICALS INC (US) | 2016-04-06 | — | — | EP | claimed |
| EP-2905336-A1 | Compositions and methods for inhibiting expression of a gene from the ebola | Alnylam Pharmaceuticals Inc. (US) | 2015-08-12 | — | — | EP | claimed |
| EP-2589660-B1 | Compositions and methods for inhibiting expression of a gene from the Ebola | ALNYLAM PHARMACEUTICALS INC (US) | 2014-11-26 | — | — | EP | claimed |
| EP-2147102-B1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A GENE FROM THE EBOLA | ALNYLAM PHARMACEUTICALS INC (US) | 2014-01-15 | — | — | EP | claimed |
| EP-2589660-A1 | Compositions and methods for inhibiting expression of a gene from the Ebola | Alnylam Pharmaceuticals Inc. (US) | 2013-05-08 | — | — | EP | claimed |
| US-7846908-B2 | RNAi modulation of TGF-beta and therapeutic uses thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-12-07 | — | — | US | claimed |
| US-4507089-A | Mechanical support module for nucleic acid | TCHUEMPE TCHUENTE GERMAIN (FR) | 1985-03-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884919-B2 | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene | SAAL1, APOB, SCARB1 | P2RY2 4259/4885TSHR 4490/4885GLA 1001/4885 |
| US-20230304058-A1 | NOVEL 5'CAP ANALOG HAVING CAP2 STRUCTURE AND PREPARATION METHOD THEREFOR | RNGTT, CAPG, CPSF7 | P2RY2 2207/4885TSHR 3997/4885GLA 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.